Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer.

ABSTRACT:

Objectives

Effective management of adverse events (AEs) following vandetanib treatment is important to maximize clinical benefits. We examined whether more frequent contact with vandetanib-treated patients reduced AEs of CTCAE grade 2 or higher.

Study design

In this open-label, multicentre, phase III study, patients with locally advanced or metastatic medullary thyroid cancer were randomized to a patient outreach programme (outreach) or a standard AE monitoring schedule (vandetanib control) for 52 weeks. In addition to standard AE monitoring, patients in the outreach arm were contacted every 2 weeks by telephone/during their clinic visit for specific AE questioning related to diarrhoea, nausea, vomiting, fatigue, headache and rash. Patients received vandetanib at 200 or 300

SUBMITTER: Bastholt L 

PROVIDER: S-EPMC5091223 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature